INT34869

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 1985
Last Reported 2011
Negated 0
Speculated 12
Reported most in Abstract
Documents 778
Total Number 790
Disease Relevance 366.76
Pain Relevance 319.85

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (PTGS2) endoplasmic reticulum (PTGS2) enzyme binding (PTGS2)
protein complex (PTGS2) cytoplasm (PTGS2) lipid binding (PTGS2)
Anatomy Link Frequency
blood 14
platelet 10
knee 10
skin 6
fibroblasts 5
PTGS2 (Homo sapiens)
PTGS2 - R106E (7) PTGS2 - S516M (2)
Pain Link Frequency Relevance Heat
cINOD 3041 100.00 Very High Very High Very High
Pain 1089 100.00 Very High Very High Very High
Inflammation 1040 100.00 Very High Very High Very High
aspirin 755 100.00 Very High Very High Very High
COX2 559 100.00 Very High Very High Very High
COX-2 inhibitor 507 100.00 Very High Very High Very High
Analgesic 405 100.00 Very High Very High Very High
Paracetamol 373 100.00 Very High Very High Very High
diclofenac 208 100.00 Very High Very High Very High
Perioperative pain 114 100.00 Very High Very High Very High
Disease Link Frequency Relevance Heat
INFLAMMATION 1896 100.00 Very High Very High Very High
Post Operative Pain 112 100.00 Very High Very High Very High
Reprotox - General 1 58 100.00 Very High Very High Very High
Apoptosis 231 99.96 Very High Very High Very High
Targeted Disruption 11 99.96 Very High Very High Very High
Pain 1120 99.92 Very High Very High Very High
Rheumatoid Arthritis 328 99.92 Very High Very High Very High
Pressure And Volume Under Development 311 99.92 Very High Very High Very High
Cv Unclassified Under Development 30 99.92 Very High Very High Very High
Headache 23 99.92 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
CONCLUSION: Selective cyclooxygenase-2 inhibition might cause severe oligohydramnios.
Negative_regulation (inhibition) of cyclooxygenase-2
1) Confidence 0.59 Published 2000 Journal Obstet Gynecol Section Body Doc Link 11094215 Disease Relevance 0 Pain Relevance 0
However, the PGHS-2 selective inhibitors nimesulide, flosulide and NS398 showed a much greater inhibition of human PGHS-2.
Negative_regulation (inhibition) of PGHS-2
2) Confidence 0.59 Published 1997 Journal Inflammopharmacology Section Abstract Doc Link 17694360 Disease Relevance 0.08 Pain Relevance 0.18
The major anti-inflammatory action of NSAIDS is to inhibit prostaglandin G/H synthase-2 (PGHS-2), the first committed enzymatic step for prostaglandin biosynthesis.
Negative_regulation (inhibit) of PGHS-2 associated with inflammation
3) Confidence 0.59 Published 1996 Journal Neurobiol. Aging Section Abstract Doc Link 8892355 Disease Relevance 0.89 Pain Relevance 0.19
To our surprise we found that PGHS-2 mRNA levels were reduced threefold in AD neocortex relative to control brain tissue.
Negative_regulation (reduced) of PGHS-2 mRNA in brain associated with disease
4) Confidence 0.59 Published 1996 Journal Neurobiol. Aging Section Abstract Doc Link 8892355 Disease Relevance 1.04 Pain Relevance 0.20
It appears that the high degree of selectivity for inhibition of PGHS-2 shown by certain compounds is the result of two mechanisms (time-dependent, time-independent inhibition), by which they interact with each isoform.
Negative_regulation (inhibition) of PGHS-2
5) Confidence 0.59 Published 2002 Journal J. Comput. Aided Mol. Des. Section Abstract Doc Link 12650588 Disease Relevance 0.17 Pain Relevance 0.27
The high degree of selectivity for inhibition of PGHS-2 shown by certain compounds appears to stem from two mechanisms (time-dependent, time-independent inhibition) by which they interact with each isoform.
Negative_regulation (inhibition) of PGHS-2 in stem
6) Confidence 0.59 Published 2002 Journal J. Mol. Graph. Model. Section Abstract Doc Link 11858641 Disease Relevance 0.17 Pain Relevance 0.27
Valdecoxib is a potent and specific inhibitor of cyclooxygenase-2, which is used for the treatment of rheumatoid arthritis, osteoarthritis, and the dysmenorrhea pain.
Negative_regulation (inhibitor) of cyclooxygenase-2 associated with pain, dismenorea, rheumatoid arthritis and osteoarthritis
7) Confidence 0.58 Published 2002 Journal Drug Metab. Dispos. Section Abstract Doc Link 12167567 Disease Relevance 0.39 Pain Relevance 0.29
The recombinant isoforms were not pharmacologically identical, since some NSAIDs were selective inhibitors of either PGHS-1 or PGHS-2.
Negative_regulation (inhibitors) of PGHS-2 associated with cinod
8) Confidence 0.58 Published 1994 Journal Biochim. Biophys. Acta Section Abstract Doc Link 7947975 Disease Relevance 0 Pain Relevance 0.18
A novel class of NSAIDs, cyclooxygenase-2 inhibitors, was introduced in 1999.
Negative_regulation (inhibitors) of cyclooxygenase-2 associated with cinod
9) Confidence 0.58 Published 2008 Journal Curr Opin Anaesthesiol Section Abstract Doc Link 18660649 Disease Relevance 0.17 Pain Relevance 0.63
Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1.
Negative_regulation (inhibits) of PGHS-2
10) Confidence 0.58 Published 1995 Journal Eur. J. Pharmacol. Section Title Doc Link 8566109 Disease Relevance 0.09 Pain Relevance 0.34
DuP697, NS-398, DFU, and SC-58125 are selective PGHS-2 inhibitors that act as time-dependent inhibitors of PGHS-2 and rapidly reversible competitive inhibitors of PGHS-1.
Negative_regulation (inhibitors) of PGHS-2
11) Confidence 0.58 Published 1997 Journal J. Biol. Chem. Section Abstract Doc Link 9083063 Disease Relevance 0 Pain Relevance 0.06
Cyclooxygenase-2 inhibitors are drugs with antiphlogistic and antirheumatic activity.
Negative_regulation (inhibitors) of Cyclooxygenase-2
12) Confidence 0.57 Published 2009 Journal Bioorg. Med. Chem. Section Abstract Doc Link 19188072 Disease Relevance 0.10 Pain Relevance 0.10
Cyclooxygenase-2 inhibitors become patients' preferred choice only if they are described as being 3 times as effective as capsaicin and are covered by insurance.
Negative_regulation (inhibitors) of Cyclooxygenase-2
13) Confidence 0.57 Published 2004 Journal Arch. Intern. Med. Section Body Doc Link 15226163 Disease Relevance 0 Pain Relevance 0
Cyclooxygenase-2 inhibition only might not induce acute gastric injury in H. pylori gastritis.
Negative_regulation (inhibition) of Cyclooxygenase-2 associated with injury and gastritis
14) Confidence 0.57 Published 2000 Journal Eur. J. Pharmacol. Section Abstract Doc Link 11040354 Disease Relevance 1.04 Pain Relevance 0.27
Valdecoxib, an orally administered cyclooxygenase-2 specific inhibitor, provides effective pain relief for both chronic and acute conditions, and reduces postoperative opioid use, with a concomitant reduction in opioid-related adverse events.
Negative_regulation (inhibitor) of cyclooxygenase-2 associated with pain and opioid
15) Confidence 0.57 Published 2005 Journal Expert Rev Neurother Section Abstract Doc Link 15853470 Disease Relevance 0.83 Pain Relevance 1.12
Cyclooxygenase-2 specific inhibitors have anti-inflammatory and analgesic properties, and are effective in managing a wide range of chronic and acute painful conditions such as adult rheumatoid arthritis, osteoarthritis, migraine, primary dysmenorrhea and postoperative pain.
Negative_regulation (inhibitors) of Cyclooxygenase-2 associated with pain, inflammation, migraine, analgesic, dismenorea, rheumatoid arthritis, perioperative pain and osteoarthritis
16) Confidence 0.57 Published 2005 Journal Expert Rev Neurother Section Abstract Doc Link 15853470 Disease Relevance 0.76 Pain Relevance 0.95
RECENT FINDINGS: Data concerning the cardiovascular risk associated with coxibs comes from three main sources: basic research demonstrating the potential for inhibitors of the cyclooxygenase-2 enzyme to promote a prothrombotic state; observational data suggesting an increased risk associated with the use of certain cyclooxygenase-2 inhibitors, and randomized trial data suggesting an increased risk associated with a variety of cyclooxygenase-2 inhibitors compared with either a traditional nonsteroidal anti-inflammatory drug, or placebo.
Negative_regulation (inhibitors) of cyclooxygenase-2
17) Confidence 0.57 Published 2006 Journal Curr. Opin. Cardiol. Section Body Doc Link 17053413 Disease Relevance 0 Pain Relevance 0
Thirteen patients with osteoid osteoma were enrolled in a prospective trial to test whether rofecoxib, a selective cyclooxygenase-2 inhibitor, is as effective for pain control as acetylsalicylic acid.
Spec (whether) Negative_regulation (inhibitor) of cyclooxygenase-2 associated with aspirin, pain and osteoid osteoma
18) Confidence 0.57 Published 2001 Journal Clin. Orthop. Relat. Res. Section Abstract Doc Link 11764357 Disease Relevance 1.05 Pain Relevance 1.00
Recognition of two different prostaglandin synthase iso-enzymes led to the development of the so-called coxibs preferentially inhibiting cyclooxygenase-2.
Negative_regulation (inhibiting) of cyclooxygenase-2
19) Confidence 0.57 Published 2005 Journal Dtsch. Med. Wochenschr. Section Abstract Doc Link 16208597 Disease Relevance 0.17 Pain Relevance 0.46
OBJECTIVES: To study the safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, and to determine whether it cross-reacts with asthma in patients with aspirin-exacerbated respiratory disease (AERD).
Negative_regulation (inhibitor) of cyclooxygenase-2 in respiratory
20) Confidence 0.57 Published 2006 Journal Ann. Allergy Asthma Immunol. Section Body Doc Link 16892790 Disease Relevance 0.19 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox